XML 41 R23.htm IDEA: XBRL DOCUMENT v3.26.1
Equity Awards (Notes)
 3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Equity Awards Equity Awards
Stock Options
Information related to stock options at March 31, 2026 is as follows:
Number of
Stock Options		Weighted Average Option PriceAverage  Remaining Contractual Life (Years)Aggregate Intrinsic Value
Outstanding at January 1, 2026900,000 $41.11 
Outstanding at March 31, 2026900,000 $41.11 9.2$780,000 
As of March 31, 2026, there was $4.4 million of unrecognized compensation cost related to stock options that is expected to be recorded over a weighted average period of 1.4 years.
The Company recognized approximately $0.7 million of stock-based compensation expense related to stock options during the three months ended March 31, 2026, and no stock-based compensation expense related to stock options during the three months ended March 31, 2025. The stock-based compensation expense is included in selling, general and administrative expenses in the accompanying consolidated statement of income.
Restricted Stock Units
The Company awarded the following restricted stock units ("RSUs") during the three months ended March 31, 2026:
•Granted 82,145 RSUs to certain employees, which are subject only to a service condition and vest ratably over two or three years so long as the employee remains with the Company;
•Granted 22,824 RSUs to its non-employee independent directors, which fully vest one year from date of grant so long as the director and/or Company does not terminate the director's service prior to the vesting date; and
•Issued 10 RSUs to certain employees related to dividend equivalent rights on existing equity awards.
During 2026, the Company also awarded 39,379 performance-based RSUs to certain Company key employees which vest three years from the grant date as long as the employee remains with the Company. These awards are initially earned 50% based upon the Company's achievement of an earnings per share ("EPS") metric and 50% based upon the Company's return on invested capital ("ROIC") metric over a period beginning January 1, 2026 and ending December 31, 2028. The total EPS and ROIC performance-based RSUs initially earned shall be subject to modification based on the Company's total shareholder return ("TSR") relative to the TSR of the common stock of a pre-defined industry peer-group, measured over the performance period. TSR is calculated as the Company's average closing stock price for the 20 trading days at the end of the performance period plus Company dividends, divided by the Company's average closing stock price for the 20 trading days prior to the start of the performance period. The Company estimates the grant-date fair value subject to a market condition using a Monte Carlo simulation model, using the following weighted average assumptions: risk-free rate of 3.74% and annualized volatility of 29.5%. Depending on the performance achieved for these two metrics, the amount of shares earned, if any, can vary for each metric from 0% of the target award to a maximum of 220% of the target.
The following disclosures related to restricted stock units include both continuing and discontinued operations.
Information related to RSUs at March 31, 2026 is as follows:
Number of Unvested RSUsWeighted Average Grant Date Fair ValueAverage Remaining Contractual Life (Years)Aggregate Intrinsic Value
Outstanding at January 1, 20261,009,137 $26.01 
  Granted144,358 35.38 
  Vested(291,005)25.23 
  Cancelled(167,217)28.00 
Outstanding at March 31, 2026695,273 $27.80 1.4$24,990,000 
As of March 31, 2026, there was $8.6 million of unrecognized compensation cost related to unvested RSUs that is expected to be recorded over a weighted average period of 2.3 years.
The Company recognized stock-based compensation expense related to RSUs from continuing operations of $2.4 million and $2.5 million during the three months ended March 31, 2026, and 2025, respectively. The stock-based compensation expense from continuing operations is included in selling, general and administrative expenses in the accompanying consolidated statement of income.